Board Change • Dec 01
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Declared Dividend • Nov 08
Dividend of ₩20.00 announced Dividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growth Duyuru • Nov 07
VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026 VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. New Risk • Sep 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Price Target Changed • Apr 04
Price target decreased by 7.2% to ₩11,420 Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year. Duyuru • Mar 12
VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025 VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea Price Target Changed • Feb 04
Price target decreased by 7.0% to ₩12,300 Down from ₩13,229, the current price target is an average from 7 analysts. New target price is 56% above last closing price of ₩7,890. Stock is up 7.3% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year. Price Target Changed • Dec 17
Price target decreased by 7.0% to ₩12,586 Down from ₩13,533, the current price target is an average from 7 analysts. New target price is 53% above last closing price of ₩8,200. Stock is down 1.1% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₩8,070, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 235% over the past three years. Price Target Changed • May 12
Price target increased by 10% to ₩12,000 Up from ₩10,875, the current price target is an average from 4 analysts. New target price is 6.6% above last closing price of ₩11,260. Stock is up 82% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩11,260, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 360% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,197 per share. Buy Or Sell Opportunity • Apr 02
Now 28% undervalued Over the last 90 days, the stock has risen 15% to ₩10,360. The fair value is estimated to be ₩14,309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 115% in the next 2 years. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩10,140, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 375% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,295 per share. New Risk • Mar 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩8,480, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,331 per share. New Risk • Feb 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Upcoming Dividend • Dec 20
Upcoming dividend of ₩10.00 per share at 0.1% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 23 April 2024. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%). Buying Opportunity • Dec 05
Now 21% undervalued Over the last 90 days, the stock is up 27%. The fair value is estimated to be ₩10,718, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 99% in 2 years. Earnings is forecast to grow by 116% in the next 2 years. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩9,590, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 277% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,842 per share. New Risk • Nov 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). New Risk • Nov 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Buying Opportunity • Aug 09
Now 20% undervalued Over the last 90 days, the stock is up 34%. The fair value is estimated to be ₩10,563, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 116% in the next 2 years. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₩6,130, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩5,740, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 185% over the past three years. Buying Opportunity • Mar 23
Now 20% undervalued Over the last 90 days, the stock is up 63%. The fair value is estimated to be ₩5,713, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last year. Earnings per share has grown by 149%. Revenue is forecast to grow by 125% in 2 years. Earnings is forecast to grow by 143% in the next 2 years. Reported Earnings • Mar 18
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: ₩198 (up from ₩80.00 in FY 2021). Revenue: ₩31.1b (up 69% from FY 2021). Net income: ₩11.5b (up 159% from FY 2021). Profit margin: 37% (up from 24% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 4.6%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Medical Equipment industry in South Korea. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩5,150, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩4,730 per share. Valuation Update With 7 Day Price Move • Jan 17
Investor sentiment improved over the past week After last week's 18% share price gain to ₩3,780, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 88% over the past three years. Buying Opportunity • Nov 28
Now 22% undervalued Over the last 90 days, the stock is up 26%. The fair value is estimated to be ₩3,332, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 139% in 2 years. Earnings is forecast to grow by 112% in the next 2 years. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: ₩68.00 (vs ₩19.00 in 3Q 2021) Third quarter 2022 results: EPS: ₩68.00 (up from ₩19.00 in 3Q 2021). Revenue: ₩7.61b (up 66% from 3Q 2021). Net income: ₩3.94b (up 267% from 3Q 2021). Profit margin: 52% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Medical Equipment industry in South Korea. Duyuru • Nov 11
VIOL Co., Ltd. (KOSDAQ:A335890) announces an Equity Buyback for KRW 3,000 million worth of its shares. VIOL Co., Ltd. (KOSDAQ:A335890) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with KB Securities co.Ltd. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on May 13, 2023. As of November 10, 2022, the company had no shares within scope available for dividend and had 21 shares in treasury through other repurchase. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment improved over the past week After last week's 16% share price gain to ₩1,990, the stock trades at a trailing P/E ratio of 14.5x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.2% over the past year. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩1,730, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 30% over the past year. Is New 90 Day High Low • Mar 09
New 90-day low: ₩2,180 The company is down 12% from its price of ₩2,475 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period. Duyuru • Nov 13
Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction. Viol Co., Ltd. agreed to acquire IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on May 11, 2020. Under the terms of transaction the merger ratio is 1: 136.682. As per the amendments on September 7, 2020, the merger ratio was changed to 1: 124.875 (Ibks No.11 Spac Co., Ltd. : Viol Co., Ltd.). Post completion, DMS Co., Ltd., largest shareholder in Viol will own a 62.43% stake in the merged company. Through this merger, Viol Co., Ltd. will actually enjoy listing on the KOSDAQ market. The transaction is subject to approval of more than two-thirds of the voting rights of participating shareholders and one-third of the total number of shares issued in IBKS No.11. The transaction has been approved by the board of directors of IBKS No.11. The transaction is expected to close on October 12, 2020. As on July 16, 2020, the transaction is expected to close on November 2, 2020. As of September 7, 2020, the transaction was expected to close on November 11, 2020. Hanul Accounting Corporation acted as the accountant to IBKS No.11 Special Purpose Acquisition Company. Hyun Accounting Corporation acted as accountant to Viol Co., Ltd.
Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on November 12, 2020. 
